Drug Profile
Research programme: asthma/allergy therapy - Johnson & Johnson Pharmaceutical Research and Development, LLC/Boehringer Ingelheim
Alternative Names: Asthma/allergy therapy research programme - 3-Dimensional Pharmaceuticals/Boehringer IngelheimLatest Information Update: 03 Mar 2008
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Johnson & Johnson Pharmaceutical Research & Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Hypersensitivity
Most Recent Events
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
- 15 May 2001 Preclinical development for Allergy in USA (Unknown route)
- 15 May 2001 Preclinical development for Asthma in USA (Unknown route)